IRLAB’s nomination committee proposes Martin Nicklasson as new board member and provides their proposal
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the nomination committee has provided their proposal and motivated opinion ahead of the annual general meeting 2021. Martin Nicklasson is proposed as a new board member. Martin Nicklasson has extensive experience from the international pharmaceutical industry, primarily from executive positions within AstraZeneca, Pharmacia, Biovitrum and Sobi as well as a board member in several life science companies.In addition to the nomination of Martin Nicklasson as a board member, the nomination committee proposes re-election of Gunnar Olsson as